Dr. Reddy’s Laboratories has launched Cefixime for Oral Suspension, USP 100 mg/5ml and 200 mg/5ml, a therapeutic equivalent generic version of Suprax (cefixime) for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA) in US markets.
The Suprax brand and generic had US sales of around $50.5 million MAT for the most recent twelve months ending in June 2017 according to IMS Health. Suprax is a registered trademark of Astellas Pharma Inc.
Dr. Reddy’s Cefixime for Oral Suspension, USP is available in strengths of 100 mg/5ml and 200 mg/5ml after reconstitution. The 100 mg/5 ml strength is available in 50 ml bottles. The 200 mg/5 ml strength is available in 75 ml and 50 ml bottles.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
